Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Hepatology CommunicationsOpen Access

Omics-driven networks herald a new era of multidimensional therapy for cholangiocarcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYuming LiuGWGanggang WangQGQiang Gao

Discussion

Loading...

Member takes

Overview

Observational analysis reveals multi-omics can identify genomic drivers in cholangiocarcinoma, suggesting better-targeted therapies.

Key Points

  • Multi-omics approaches can unravel complex mechanisms of cholangiocarcinoma, enabling personalized therapies.
  • FGFR2 fusions are rare in cholangiocarcinoma, highlighting the need for broader molecular profiling in treatment.
  • Immunotherapy combined with targeted therapy has shown promising outcomes, particularly in patients with IDH mutations.
  • Drug resistance remains a major challenge, requiring innovative strategies to profile and adapt therapies continuously.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64785afehttps://doi.org/10.1097/hc9.0000000000000809
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrated Systems Oncology: A Multimodal Framework for Addressing Cancer Heterogeneity2025
  2. 2Editorial: Formation of immunological niches in tumor microenvironments: mechanisms and therapeutic potential2025 · 2 citations
  3. 3Applications and advances of multi-omics technologies in gastrointestinal tumors2025 · 10 citations
  4. 4Cancer: From a Genetic Disorder to a Systemic Disease2025
  5. 5Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment2025